Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30.
It has previously been found that insulins, to which positive charge has been added by substitutions in position B30, thus raising the isoelectric point towards pH 7, had a prolonged action when injected as slightly acidic solutions because such derivatives crystallize very readily upon neutralization. Positive charge has now been added by substituting the B13 and A17 glutamic acid residues with glutamines and B27 threonine with lysine or arginine. These substitutions were introduced by site-specific mutagenesis in a gene coding for a single-chain insulin precursor. By tryptic transpeptidation the single-chain precursors were transformed to the double-chain insulin structure, concomitantly with incorporation of residue B30. Thus insulins combining B13 glutamine, A17 glutamine and B27 lysine or arginine with B30 threonine, threonine amide or lysine amide were synthesized. The time course of blood glucose lowering effect and the absorption were studied after subcutaneous injection in rabbits and pigs. The prolonged action of B30-substituted insulins was markedly enhanced by B27 lysine or arginine substitutions and by B13 glutamine. The B27 residue is located on the surface of the hexamer, so a basic residue in this position presumably promotes the packing of hexamers at neutral pH. The B13 residues cluster in the centre of the hexamer. When the electrostatic repulsive forces from six glutamic acid residues are abolished by substitution with glutamine, a stabilization of the hexamer can be envisaged.(ABSTRACT TRUNCATED AT 250 WORDS)
Markussen
J
J
Novo Research Institute, Bagsvaerd, Denmark.
Diers
I
I
Engesgaard
A
A
Hansen
M T
MT
Hougaard
P
P
Langkjaer
L
L
Norris
K
K
Ribel
U
U
Sørensen
A R
AR
Sørensen
E
E
D000595:Amino Acid Sequence; D000818:Animals; D001483:Base Sequence; D001786:Blood Glucose / Q000378:metabolism; D003460:Crystallization; D003692:Delayed-Action Preparations; D005260:Female; D005813:Genes, Synthetic; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000235:genetics; D008969:Molecular Sequence Data; D015202:Protein Engineering; D011817:Rabbits; D012995:Solubility; D013552:Swine
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D007328:Insulin